Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.